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Abstract
Population-based assessments of physical health are important to evaluate healthcare resource allocation. Normative
data on the level of physical impairments attributable to specific diseases and severity levels within these diseases is
critical to interpreting such data. Our objective, by means of a systematic review and meta-analysis, was to test
the hypothesis that specific diseases which form cardiovascular and musculoskeletal disease spectra are associated with
gradients of physical impairments. We examined a cardiovascular disease spectrum which consisted of hypertension,
ischaemic heart disease and heart failure, and a musculoskeletal disease spectrum of lower back pain, osteoarthritis and
rheumatoid arthritis. Using Medline, EMBASE and CINAHL databases, articles which had examined these morbidities and
used either the SF-12 or SF-36 in general or primary care populations were selected; data was extracted independently by
three reviewers. Study characteristics were described and the mean physical component summary scores of the SF-12 or
SF-36 was analysed by disease, using random-effects meta-analysis. The association between disease and physical health
(mean physical component summary scores) was assessed using multilevel meta-regression analysis, adjusting for age,
health setting, country, disease definition and SF-12 or 36 format. From this search, 26 articles were identified, yielding 70
separate estimates of mean physical component summary scores across the morbidities from 14 different countries. For
the selected conditions, pooled unadjusted mean physical component summary scores were: 44.4 for hypertension, 38.9
for ischaemic heart disease, 35.9 for heart failure, 39.5 for lower back pain, 36.0 for osteoarthritis and 36.5 for rheumatoid
arthritis. The adjusted meta-regression showed mean physical component summary score difference for ischaemic heart
disease of −4.6 (95 % confidence interval −6.0 to −3.2) and heart failure −7.5 (−9.1 to −5.9) compared to the hypertension
category. For osteoarthritis −4.2 (−5.3 to −3.0) and rheumatoid arthritis −3.9 (−9.5 to 1.6) compared to the lower back pain
category. Our findings provide the benchmark norms for the differences in physical health within and between disease
spectra. Improved characterisation of the relative impact of individual conditions on physical health will facilitate public
health assessments of chronic diseases as well as assessments of interventions using functional patient-reported outcomes.
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Introduction
Research has shown the influence of specific chronic dis-
eases on patients’ self-reported health status and found the
magnitude of this to vary by disease [1, 2]. For example,
both Ischaemic Heart Disease (IHD) and Osteoarthritis
(OA) will adversely impact on physical health, but the rela-
tive impact of these two diseases in a patient population
may vary [3, 4]. Chronic diseases often include conditions
at differing stages of development, which means that each
chronic disease is in fact a spectrum of conditions. IHD is
only one example in a cardiovascular disease spectrum,
ranging from hypertension to severe cardio or cerebrovas-
cular conditions, which are linked by pathophysiology [5].
In contrast OA is just one example of a pain condition in a
musculoskeletal disease spectrum, which can range from
localised pain symptoms to more systemic conditions such
as Rheumatoid Arthritis [6]. In this spectrum the links are
based on the common symptom of pain, as opposed to
shared pathophysiology.
For public health, the importance of this ‘spectrum’ ap-
proach is that it provides a population perspective of the
range of conditions which may be associated with differ-
ing physical health impairments, with the implication
that differing interventions may be required.
This conceptual approach of spectra is under-pinned
by our previous clinical and epidemiological studies [7–9]
and provides the opportunity to examine the concept of
‘relative severity’, i.e. how individual conditions influence
health within the same chronic disease spectrum relative
to one another [10]. This definition of ‘relative severity’ of
different health conditions is based on previous GP focus
groups, where the criteria for classifying severity were
developed using clinical data and defined into four cat-
egories: i) chronicity and threat, ii) time course, iii)
health care use, iv) impact on patients’ Activities of
Daily Living (ADL)). Following this, a further 118 GPs
took part in a consensus study to agree the severity def-
initions for a total of 188 morbidities. These methods
were then tested in both English and Dutch general
practice populations [8, 9].
Our rationale to examine different conditions, ranked
a priori based on their severity within a spectrum is
based on the knowledge that the ‘severity’ of a health
condition frequently influences its clinical management.
By understanding the state of a given condition within a
spectrum, this can provide additional insight into a
particular outcome and subsequent clinical decision-
making. Therefore, knowledge of severity of condi-
tions on a population level can add to the information
aiding treatment and management choices.
Over recent decades, the measurement of overall health
and physical health impairment using standardised
questionnaires has become routine as a basis for measuring
disease-related outcomes and focused on obtaining patient-
centred outcomes data in international research and clinical
practice. The most commonly used of such general health
and well-being measures in population-based studies are
the SF-12 & SF-36 health surveys [11]. The accumulation
of such evidence provides the basis for benchmarking
norms for the differences in physical health within and be-
tween chronic diseases. Synthesis of this evidence would
provide population-based assessments of physical health for
evaluation of healthcare resource allocation and the norma-
tive data that would be critical to interpreting such physical
health data.
Whilst there is any number of spectra that could be
tested under this hypothesis, the focus in this paper is
on two spectra of common disease in populations, car-
diovascular disease (CVD) and musculoskeletal disease
(MSD) [6, 8]. To make the hypothesis testable and feasible,
we a priori selected three specific morbidities for each
spectrum and based their order of severity classification
on our previous research. For the CVD spectrum; we
chose the common and linked morbidities of hyperten-
sion, Ischaemic Heart Disease (IHD) and Heart Failure
(HF) [12]. For the MSD spectrum, we chose the morbid-
ities for which pain symptoms are a common experience,
Lower Back Pain (LBP), Osteoarthritis (OA) and Rheuma-
toid Arthritis (RA) [13]. Using the three stated examples
for the CVD and MSD spectra, we undertook a systematic
review to examine the current evidence on the physical
health status of these conditions, measured using the SF-
12 or SF-36 [14, 15], in general populations or primary
care populations. The objectives using systematic review
and meta-analysis methods were; 1) to examine how phys-
ical health differs within a CVD and MSD spectrum and
2) to examine whether physical health differs between the
two specified chronic disease spectrums.
Methods
A systematic review, meta-analysis and meta-regression
of identified research articles were conducted. Medical
literature databases were searched to identify articles
which included study samples defined with at least one
of six specified conditions (hypertension, IHD and HF;
and LBP, OA and RA), and which had reported a physical
health outcome in the general population or primary care
population. Selection of articles was based on standardised
inclusion and exclusion criteria. Initial comparisons of
the mean PCS scores were made using meta-analysis; a
meta-regression was used to examine pooled and ad-
justed estimates for each condition and compared
within and between the two spectrums.
Chronic disease spectra
For CVD, the systematic review focused on hypertension,
IHD and HF articles. Where an article included patients
who had been defined as having IHD, angina or myocardial
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infarction (MI), all were defined within the IHD category.
For MSD, the focus was on LBP, OA and RA articles.
Within each spectra, use of the three conditions is justified
for such examination based on their distinct severity and
symptom profiles at a population level. Conditions were
placed in a priori order of severity, based on previous clin-
ical and validation studies in English and Dutch populations
[7, 8] and the distinct spread of symptom experience for
these conditions within their respective chronic diseases
meant that conditions could be ordered from ‘less severe’
(i.e. hypertension for CVD and LBP for MSD) to those
defined as ‘moderately severe’ (i.e. IHD for CVD and
OA for MSD), and to ‘most severe’ (i.e. HF for CVD
and RA for MSD).
Article selection
Standard search strategies were carried out in the three
databases of Medline, EMBASE and CINAHL, using
the National Health Service (NHS) evidence webpage
(https://www.evidence.nhs.uk/). Selection of an article
into the final review was based on inclusion criteria
which included; (i) study samples being aged ≥18 years,
(ii) recruited either from the general population or
primary care and (iii) defined as having one of the six
study specified conditions of interest. Only observa-
tional studies were included in the review.
The primary measure of physical health for studies in
this review was the Physical Component Summary
(PCS) score from either the SF-12 or SF-36. Both the
SF-12 & SF-36 surveys form aggregate scores of general
physical health, the PCS score and general mental
health, the Mental Component Summary (MCS) score.
These scores are normalised to a general US population
mean of 50 (Standard Deviation (SD) 10), scores below
50 indicate worse physical or mental health than the
‘average’ US population [16]. The use of these summary
scores across the selected articles allowed the comparison
of different conditions in populations [17–20].
Exclusion criteria were (i) specifically sampling pa-
tients only aged 17 years or under, (ii) articles published
pre-1990 (these SF surveys were developed from the late
1980s and not used prior to the 1990s [14]), (iii) related
to a randomised control trial (RCT) design, or iv) non-
English language articles due to limited resources for
translation. In articles including both baseline and
follow-up longitudinal data from observational studies,
only the baseline data was included into the analysis.
Search and selection strategies
This systematic review implemented nine search strat-
egies in total, as a result of conducting three chronic
disease specific searches (“cardiovascular”, “musculo-
skeletal” and “chronic”) in the three literature databases
(Additional file 1: Table S1a-c). Each search strategy
was based on ‘exploded’ Medical Subject Heading (MeSH)
terms and individual keywords.
The selection of articles was based on; title screening,
abstract screening, and then review of the full article,
using a total of three reviewers (JAP, KPJ, UTK). Titles
were screened by the first reviewer (JAP), and the list of
abstracts for inclusion or exclusion generated. Two re-
viewers (UTK & KPJ), blinded to the abstract selections
of the first reviewer, completed the abstract selection
by reviewing half the total number of abstracts each.
Disagreements on inclusion or exclusion of articles
were resolved using a triangulation process.
The full articles included in the review underwent
structured data extraction. Each article could have exam-
ined the influence of several of the six specified conditions
of interest. The mean PCS scores for each condition, and
a measure of distribution around the mean; (Standard
Deviation (SD)), were extracted. Other information ex-
tracted included: the lead author and publication year;
sample size, along with their mean age (SD), the health
care setting (general population or primary care), method
of condition definition, samples’ country and SF format
used (SF-12 or SF-36). In the instances where an article
was included in the review, but the required data were not
reported, the corresponding author was contacted and the
data requested directly.
Data synthesis & analysis
Mean PCS scores for each condition were initially com-
pared through meta-analysis and presented as forest
plots. For each condition, articles were ordered by the
region from which they came; Europe (subdivided into
Northern, Eastern, Southern or Western Europe), North
America or Asia. These forest plots provided a graphical
representation of the mean PCS score by; i) article, ii)
condition and iii) each chronic disease overall. This un-
adjusted analysis used a random-effects meta-analysis
model. For IHD, where separate estimates for ‘IHD only’,
‘angina’ and ‘MI’ were given in a study, these were com-
bined where appropriate.
Multilevel meta-regression [21] was used to compare
the pooled mean PCS scores between the conditions.
This method takes into account the potential clustering
effects within studies examining more than one of the
selected conditions (for example, patients in both the
hypertension and heart failure condition categories).
A separate meta-regression was conducted for CVD
and MSD to examine the within spectrum association
with mean PCS score (reference categories were; hyperten-
sion for CVD & LBP for MSD). Following that, a further
meta-regression was conducted to examine the between
spectra association with mean PCS score compared to the
reference category (hypertension) mean PCS score. Differ-
ence in PCS scores from the reference category in each set
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of analysis were defined as a ‘Minimal Clinically Importance
Difference’ (MCID) if the PCS score was 3 points or greater
[22]. Meta-regressions were adjusted for age, health setting,
country, method for defining condition and format of the
SF survey. Each of these variables represents a potential
source of variation in the SF estimate.
Each variable was dichotomised, these binary variables
included; mean dataset age (≤59 or ≥60 years); health
setting (general population or primary care); country
(Europe or ‘Rest of the world); method of condition defin-
ition (self-report or ‘other method) and finally, whether
the SF-12 or SF-36 had been used. Within spectrum meta-
regression was reported as i) unadjusted values, ii) ad-
justed for age and iii) adjusted for all other stated variables
mentioned above. Between spectra meta-regression is only
reported with adjustment for all stated variables. Analyses




From the total of 3,384 unique articles identified, after
exclusion, 122 were reviewed in full. From these 122
articles, 20 met the inclusion criteria and an additional
six articles were identified through the reference lists of
the included 20. This process resulted in 26 articles fi-
nally being included in the systematic review (Fig. 1).
The 26 articles included in this review were from 14
different countries, incorporating a total of 70 estimates
of mean PCS scores across the six specified conditions
and for a total population of 43,840 individuals. For the
CVD spectrum, this review identified 22 estimates for
hypertension [4, 10, 24–36], 19 estimates for IHD [4, 10,
27, 33, 36, 37] and 12 for HF [10, 27, 36, 38, 39]. CVD
studies were predominantly from European countries, with
several also from the US & Asia. For the MSD spectrum,
six mean PCS estimates for LBP [4, 10, 31, 40–42], seven
for OA [3, 10, 31, 33, 41, 43] and four for RA [25, 44–46]
were identified. MSD studies were predominantly from
European countries, with several also from the US.
At the point of meta-analysis, IHD articles having ex-
amined more than one IHD sample (i.e. MI & angina)
were pooled. Therefore, a total of 64 estimates of mean
PCS scores were finally used in the meta-analysis and
meta-regression, 13 of which were categories as IHD, con-
densed from the original 19.
Fig. 1 Selection of studies for inclusion in review
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CVD spectrum and physical health
The 22 estimates of PCS scores in hypertension samples
came from 15 articles in 12 countries, with a combined size
of 27579. The mean ages of these samples ranged from
42.9–68.1 years, with just over half from the general popu-
lation. The 19 estimates of PCS scores in IHD samples
came from six articles in 11 countries with a combined size
of 3641. Half of these came from the general population
with mean ages ranging from 43.3–70.2 years. For HF there
were 12 estimates of PCS scores from five articles in eight
countries with a combined sample of 1985. Mean ages
of these samples ranged from 57.4–76.5 years, with two
thirds from general population samples (Additional file 2:
Tables S2a-c).
Estimates from the initial meta-analyses showed the fol-
lowing summary scores: for hypertension pooled mean
PCS score was 44.4 (95 % CI 43.4 to 45.2); IHD was 38.9
(36.9 to 41.0) and for HF was 35.9 (34.1 to 37.6) (Fig. 2).
Fig. 2 CVD forest plot
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Meta-regression of CVD studies
The unadjusted meta-regression showed an association
between increasing CVD severity and poorer physical
health (Table 1). Compared to the US general population
mean of 50, the unadjusted mean PCS score was six
points lower for hypertension, 11 points lower for IHD,
and 14 points lower for HF. When adjusted for age, dif-
ferences between the CVD conditions remained, but did
decrease in magnitude. With hypertension as the refer-
ence group, the age-adjusted pooled mean PCS score
for both IHD (−4.6 (−5.9 to −3.2)) and for HF (−7.3
(−9.1 to −5.9)) were significantly lower. The final stage
of adjustment for health setting, country, condition def-
inition and SF-12 or 36 formats had minimal influence
on these associations, which remained significant.
MSD spectrum and physical health
The six estimates of mean PCS scores for LBP were
from separate articles from six different countries, with a
combined size of 2433. Mean ages ranged from 49.9–
81 years, with four drawn from primary care. There were
seven estimates of mean PCS scores for OA from seven
articles, in six different countries with a combined size
of 7582. Mean ages ranged from 43.3–71.0 years, with
all but one study conducted in primary care. Finally, the
four estimates of mean PCS scores for RA came from
four articles in three countries with a combined size of
2620. Three of the four were based in primary care and
mean ages ranged from 53.9–61.3 years old (Additional
file 2: Tables S2d-f ).
Estimates from the initial meta-analyses showed the
following summary scores: for LBP pooled mean PCS
score was 39.4 (35.9 to 43.0); OA was 36.0 (33.3 to 38.6)
and for RA was 36.5 (33.6 to 39.4) (Fig. 3).
Meta-regression of MSD studies
The unadjusted meta-regression showed similar associa-
tions of OA and RA having poorer physical health com-
pared to the LBP category. Compared to the US average,
the unadjusted mean PCS score was 10 points lower for
LBP, 14 points lower for OA, and 13 points lower for RA.
With LBP as the reference group, the age-adjusted pooled
mean PCS score for both OA (−4.2 (−5.3 to −3.1)) and RA
(−4.1 (−7.9 to −0.3)) was significantly lower. Further ad-
justment for health setting, country, condition definition
and SF-12 or SF-36 format had minimal influence on the
magnitude of associations with OA, but the association
for RA became non-significant (Table 1).
Comparison between spectrums
Compared to hypertension, the adjusted pooled mean
PCS score for LBP was non-significantly lower by −1.7
(−3.6 to 0.2), whilst OA was significantly lower by −5.1
(−6.9 to −3.3) and RA significantly lower by −6.0 (−9.5
to −2.5). The adjusted estimates of pooled PCS scores
for hypertension and LBP were similar, as were those of
IHD and OA, and for HF and RA (Table 1).
Discussion
Overall findings
This systematic review and meta-analysis provides
population-based estimates of physical health limitations
associated with cardiovascular and musculoskeletal dis-
eases from international studies. For CVD, the gradient
in associations from hypertension to IHD to HF, provide
an indicative health status of populations and the potential
change in physical health across the CVD spectrum as
populations go from a single cardiovascular disease (such
as hypertension) to more complex end-stage conditions
such as heart failure. For the MSD spectrum, there was







PCS score (95 % CI)
Unadjusted difference in
mean PCS score (95 % CI)
Age adjusted difference in
mean PCS score (95 % CI)
Adjustedb difference in
mean PCS score (95 % CI)
Adjustedb difference in
mean PCS score (95 % CI)
Cardiovascular diseases
Hypertension 44.4 (43.5 to 45.2) Ref Ref Ref Ref
Ischaemic Heart
Disease
38.9 (36.9 to 41.0) −5.3 (−6.4 to −4.1) −4.6 (−5.9 to −3.2) −4.6 (−6.0 to −3.2) −4.8 (−6.2 to −3.5)




39.4 (35.9 to 43.0) Ref Ref Ref −1.7 (−3.6 to 0.2)
Osteoarthritis 36.0 (33.3 to 38.6) −4.3 (−5.4 to −3.2) −4.2 (−5.3 to −3.1) −4.2 (−5.3 to −3.0) −5.1 (−6.9 to −3.3)
Rheumatoid
Arthritis
36.5 (33.6 to 39.4) −2.7 (−4.3 to −1.1) −4.1 (−7.9 to −0.3) −3.9 (−9.5 to 1.6) −6.0 (−9.5 to −2.5)
aaccounting for clustering within studies using multilevel meta-regression
bAdjusted for: age, health setting, location, method of disease definition & SF-12 or SF-36 format
Prior et al. Health and Quality of Life Outcomes  (2015) 13:71 Page 6 of 10
less of a gradient in the three chosen conditions which in-
dicates that associated poor health might not develop
across the pain-spectrum conditions as hypothesised.
Within the CVD spectrum, the mean PCS score esti-
mates of hypertension and IHD were comparable to
those of the same disease groups from US normative
disease group data. Our estimates for hypertension 44.4
and for IHD 38.9, were comparable to those reported in
the derived SF-12 US normative median values of 45.5
and 38.1 respectively [47]. Such similarity of these crude
PCS scores suggests our estimates provide an accurate
baseline from which to consider the adjusted differences
between conditions.
After adjustment for age and other study-design fac-
tors, the differences within the selected CVD spectrum
were greater than 3 points, which can be considered a
minimal clinically important difference [22, 48]. Such
differences provide the public health estimation of phys-
ical health impairments within the CVD spectrum as
these related conditions develop. In current public
health approaches, interventions are tailored to the CVD
spectrum for the reduction in mortality outcomes [49, 50].
Therefore, such an existing framework could be applied to
the characterisation of relative impact of chronic diseases
on physical health. This will facilitate public health assess-
ments of chronic disease progression as well as assessments
of interventions using functional patient-reported out-
comes. For example, population level benchmark
norms could be used to produce clinical guidance on
when interventions to improve physical health should
be introduced during the course of a progressing
chronic disease, such as CVD.
Whilst all three selected MSD were associated with
poorer physical health compared to the general US
population, the relative differences between the conditions
were less distinct than the CVD spectrum. It is arguable
here that public health approaches to these types of MSD
need to focus on the pathology of the pain condition as
opposed to quality of life in such populations [51–53].
Though the relative adjusted difference was deemed clin-
ically important and significant for OA and RA (4 points
lower) compared to LBP, crude estimates were not com-
parable to US disease specific norms. Our crude estimate
for LBP was much poorer (10 points) than mean scores
determined for the same disease group from normative
US data (39.4 vs. 48.6 respectively). Estimates for OA &
Fig. 3 MSD forest plot
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RA were also poorer than normative disease specific data.
However, we did observe a similar impact on mean PCS
score estimates for OA & RA (36.0 & 36.5 respectively)
which was also shown by the US normative disease
specific data (39.0 & 40.9 respectively) [47]. Here the
findings suggest a severe, but similar influence of the
MSD conditions on physical health, but do not support
the MSD gradient.
In public health terms, the importance of these findings
here is that for this CVD spectrum we have quantified a
gradient of physical health in different conditions. Though
it could be argued that comorbidity is contributing to such
poor physical health, it still remains that populations with
serious CVD such as heart failure will have poorer health,
no matter the direct cause. However, for MSD, it may be
the experience of any MSD condition that is important
and not necessarily what type.
The findings between chronic disease spectra suggest
that the associations with poor physical health status can
be similar in populations that might experience CVD or
MSD. The adjusted estimate of physical health score for
LBP was not statistically different from hypertension,
IHD was equivalent to OA, and HF was similar to RA.
Such results give additional support to our constructed
spectra, as results are comparable across the ‘less’,
‘moderately’ and ‘most’ severe conditions displaying
similar impacts on physical health. In public health
terms, the importance of these comparable findings is
the suggestion that, on a population level, any CVD
and MSD conditions of a similar ‘severity level’ may
be important in the influence on physical health and
not necessarily the specific type of condition.
Strengths and limitations
This systematic review and meta-analysis identified the
key international studies that had investigated the asso-
ciation between chronic disease and physical health
measured using a standardised instrument. This was
achieved by the a priori test of relative severity, ordering
diseases within the same chronic disease spectrum. The
selection of the two spectra, both formed from common
conditions, provides the comparison of physical health
estimates and the practical approach to devising com-
parisons within and between different chronic diseases.
In using data drawn from international studies, the
caveat is that heterogeneity for the selected condition
categories might be the partial explanation for some of
the differences identified, despite the adjustment for the
study design and setting. Whilst, specific conditions such
as heart failure, ischaemic heart disease, osteoarthritis
and rheumatoid arthritis have defined diagnostic criteria
[54–57], conditions such as hypertension and lower back
pain criteria might differ. The scope of the review was
international and most studies were of an appropriately
large sample size, however the exclusion of articles not
written in English, might have introduced selection issues.
It could be argued that the MSD examples had reduced
power to detect the range of physical impairments because
of the small number of studies identified. Finally, though
each condition in the CVD or the MSD spectrum were in-
dicators of the likely physical impairment, the analyses
did not account for comorbidity, other than adjusting
by age as a proxy marker. Conditions such as heart fail-
ure or rheumatoid arthritis often accrue comorbidity as
a result of age and complication, and the physical im-
pairment therefore may in part be a reflection of the index
HF or RA, or also any associated comorbidity.
Conclusions
Our systematic review and meta-analysis describes the
relative physical limitations associated with spectra of
cardiovascular and musculoskeletal diseases. The findings
provide benchmark norms for the differences in physical
health both within and between diseases. Improved char-
acterisation of the relative impact of health conditions on
physical health will facilitate public health assessments of
chronic disease, as well as population-based assessments
of clinical interventions using functional outcomes which
are meaningful to patients.
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